Gyre Therapeutics's market cap is currently ―. The company's EPS TTM is $-17.572; its P/E ratio is -0.84; Gyre Therapeutics is scheduled to report earnings on March 26, 2024, and the estimated EPS forecast is $-0.60. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	$ 96.00K	-	$ 0.00
Gross Profit	-	-	$ 96.00K	-	$ 0.00
EBIT	$ -1.58M	$ -2.47M	$ 274.00K	$ -39.73M	$ -4.88M
EBITDA	$ -1.58M	$ -2.47M	$ 277.00K	$ -39.72M	$ -4.84M
Net Income Common Stockholders	$ -1.58M	$ -2.47M	$ 260.00K	$ -40.45M	$ -4.88M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 2.23M	$ 6.92M	$ 8.10M	$ 21.67M	$ 23.09M
Total Assets	$ 9.96M	$ 12.39M	$ 18.75M	$ 28.44M	$ 31.02M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 38.00K	$ 381.00K
Net Debt	$ -2.23M	$ -6.92M	$ -8.10M	$ -21.63M	$ -22.71M
Total Liabilities	$ 6.45M	$ 7.40M	$ 11.39M	$ 16.82M	$ 1.64M
Stockholders Equity	$ 3.52M	$ -28.31M	$ -25.95M	$ -21.69M	$ 29.38M
Cash Flow	-
Free Cash Flow	$ -3.22M	$ -2.47M	$ -5.22M	$ -1.42M	$ -7.28M
Operating Cash Flow	$ -3.22M	$ -2.47M	$ -6.22M	$ -1.48M	$ -7.28M
Investing Cash Flow	-	$ 4.79M	$ 411.00K	$ 51.00K	$ 0.00
Financing Cash Flow	$ -1.48M	$ -3.50M	$ -7.76M	-	$ -45.03M

Currency in USD

Gyre Therapeutics Earnings and Revenue History

Income Statement >

Gyre Therapeutics Debt to Assets

Balance Sheet >

Gyre Therapeutics Cash Flow

Cash Flow >

Gyre Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing